<Suppliers Price>

Darovasertib (LXS-196)

Names

[ CAS No. ]:
1874276-76-2

[ Name ]:
Darovasertib (LXS-196)

[Synonym ]:
2-Pyrazinecarboxamide, 3-amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-
3-Amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-2-pyrazinecarboxamide
NVP-LXS196
LXS196

Biological Activity

[Description]:

LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma.

[Related Catalog]:

Signaling Pathways >> Epigenetics >> PKC
Signaling Pathways >> TGF-beta/Smad >> PKC
Research Areas >> Cancer

[Target]

PKC


[In Vitro]

Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1].

[References]

[1]. Protein Kinase C Inhibitor LXS196


[Related Small Molecules]

12-O-tetradecanoylphorbol-13-acetate | Staurosporine | Midostaurin | Go 6983 | Bisindolylmaleimide I (GF109203X) | Sotrastaurin | Ro-318220 | Chelerythrine chloride | Enzastaurin (LY317615) | Ruboxistaurin hydrochloride | Beta-Amyloid(1-40) | CGP60474 | (-)-Indolactam V | HA-100 | Acteoside

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
592.7±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C22H23F3N8O

[ Molecular Weight ]:
472.466

[ Flash Point ]:
312.3±30.1 °C

[ Exact Mass ]:
472.194702

[ LogP ]:
3.70

[ Vapour Pressure ]:
0.0±1.7 mmHg at 25°C

[ Index of Refraction ]:
1.622

[ Storage condition ]:
2-8℃

Related Compounds